From the Journals

A New Psychotherapeutic ‘Gold Standard’ for Chronic Pain?


 

More Work Needed

In an accompanying editorial, Matthias Karst, MD, PhD, a clinician with the Pain Clinic, Hannover Medical School, in Hannover, Germany, noted that EAET’s effects “are significantly superior to those of CBT in almost all dimensions, even after 6 months.”

EAET “assigns a special place to the integration of the body into the emotional experience,” he wrote.

The study demonstrated that “the evocation and expression of emotions is superior to the mere cognitive discussion of these emotions in therapy of patients with chronic pain.”

Commenting on the findings, Traci J. Speed, MD, PhD, assistant professor of psychiatry and behavioral sciences and an attending psychiatrist of the Johns Hopkins Pain Treatment Program at Johns Hopkins University, Baltimore, called the study “ground-breaking” because it showed effectiveness in people with high rates of PTSD, anxiety, and depression.

“It is a little bit surprising how impressive the study outcomes are in terms of maintaining the effects at the end of the treatment and sustaining some of the effects on pain sensitivity even at the 6-month follow-up,” said Dr. Speed, who was not part of the study.

However, she continued, “I don’t think it changes the current standard of practice yet. CBT has decades of research and evidence that it is effective for chronic pain and that will I think continue to be the standard of care.”

Although EAET is in its infancy, chronic pain experts are interested in learning more about the therapy, Dr. Speed added.

“It blends well with the current techniques and extends the current gold standard treatment approaches,” she said. “We are starting to really appreciate the role that emotions play in pain sensitivity.”

Both Dr. Karst and Dr. Speed noted that more study is needed to determine the sustainability of treatment effects.

Dr. Yarns agreed. “We need more research on what the appropriate dose is and perhaps how one might go about personalizing that for the patient,” he said.

The study was funded by a career development award to Dr. Yarns from the VA Clinical Science Research and Development Service. Dr. Yarns reported receiving grants from the US Department of Veterans Affairs during the study. Other authors’ disclosures are in the original article. Dr. Speed reported no conflicts.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

Chronic Fatigue Syndrome and Fibromyalgia: A Single Disease Entity?
MDedge Psychiatry
FDA Recommends DEA Move Cannabis From Schedule I to III
MDedge Psychiatry
No Impact of Legalized Cannabis on Opioid Prescriptions, Mortality
MDedge Psychiatry
Chronic Pain Linked to Accelerated Brain Aging
MDedge Psychiatry
Tension, Other Headache Types Robustly Linked to Attempted, Completed Suicide
MDedge Psychiatry
IV Ketamine Promising for Severe Refractory Headache in Children
MDedge Psychiatry
The DEA Plans to Reschedule Marijuana: What Happens Next?
MDedge Psychiatry
Post–Mohs Surgery Opioid Prescribing More Common in Some Patient Groups
MDedge Psychiatry
Chronotherapy: Why Timing Drugs to Our Body Clocks May Work
MDedge Psychiatry
DEA Training Mandate: 8 Hours of My Life I’d Like Back
MDedge Psychiatry